Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1679055 | 1.00 | EPHX1 (0.47) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL1679057 | 1.00 | EPHX1 (0.47) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL49195 | 0.96 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL7647781 | 0.96 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL2917831 | 0.96 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL49353 | 0.96 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL819653 | 0.96 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL7644168 | 0.96 | EPHX1 (0.50) | EPHX1HIF1AALDH1A1SIGMAR1HSD17B10 | |
| SCHEMBL1678970 | 0.96 | — | — | |
| SCHEMBL49819 | 0.92 | EPHX1 (0.44) | EPHX1HIF1AALDH1A1SIGMAR1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| EP-1207161-B1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2006-01-18 | — | — | EP | disclosed |
| US-6777410-B2 | SUCH AS 9-(2-METHOXYPHENYL)-3-(1-METHYLETHYL)-(1,3)OXAZOLO-(2,3)ISOINDOLE-2,5(3H,9H)-DIONE; DIABETES AND COMPLICATIONS; OBESITY | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-08-17 | — | — | US | disclosed |
| US-20040053923-A1 | Novel isoindole derivatives | BANYU PHARMACEUTICAL CO., LTD. | 2004-03-18 | — | — | US | disclosed |
| US-6608098-B1 | Diabetes or obesity, 2-(4-(3-isopropyl-2,5-dioxo-2,3-dihydro-1H-pyrrolo(2,1-a) isoindol-9(5H)-yl)phenoxy)-N-propylacetamide | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-08-19 | — | — | US | disclosed |
| EP-1207161-A1 | NOVEL ISOINDOLE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-22 | — | — | EP | disclosed |
| EP-0796248-B1 | CARBOSTYRIL DERIVATIVES AS ANTITHROMBOTIC AGENTS | WESTERN THERAPEUTICS INST D (JP) | 2001-08-16 | — | — | EP | disclosed |
| US-6143763-A | Carbostyril derivatives | D. WESTERN THERAPEUTICS INSTITIUTE (JP) | 2000-11-07 | — | — | US | disclosed |
| CN-1172478-A | Quinolone derivative antithrombotic agent | OTSUKA PHARMA CO LTD (JP) | 1998-02-04 | — | — | CN | disclosed |
| EP-0796248-A1 | CARBOSTYRIL DERIVATIVES AS ANTITHROMBOTIC AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-24 | — | — | EP | disclosed |
| WO-1997012869-A1 | CARBOSTYRIL DERIVATIVES AS ANTITHROMBOTIC AGENTS | OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) | 1997-04-10 | — | — | WO | disclosed |
| US-5204353-A | 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith | CIBA-GEIGY CORPORATION (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0288431-B1 | 3H-1,2,3-triazolo[4,5-d]pyrimidines | CIBA-GEIGY AG (CH) | 1992-08-19 | — | — | EP | disclosed |
| US-5110818-A | Antiepileptic agents | CIBA-GEIGY CORPORATION (US) | 1992-05-05 | — | — | US | disclosed |
| EP-0363320-A2 | Substituted 9H purine | CIBA-GEIGY AG (CH) | 1990-04-11 | — | — | EP | disclosed |
| EP-0288431-A1 | 3H-1,2,3-triazolo[4,5-d]pyrimidines | CIBA-GEIGY AG (CH) | 1988-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255111-A1 | Tissue Factor Production Inhibitor | PTAFR, PLAT, TFPI | EPHX1 838/4885HIF1A 489/4885ALDH1A1 4330/4885 |
| US-20040053923-A1 | Novel isoindole derivatives | GPR119, SLC5A2, SLC5A1 | EPHX1 3176/4885HIF1A 193/4885ALDH1A1 228/4885 |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | NR1H2, NR1H3, NCOR2 | EPHX1 1845/4885HIF1A 1774/4885ALDH1A1 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.